Wednesday, February 27, 2013

• Dynavax: A Takeover Target?at Seeking Alpha (Wed, Feb 27)

Tuesday, February 26, 2013

• Should I Invest in GlaxoSmithKline?at Motley Fool (Tue, Feb 26)
• Glaxo Shells Out $7.5 MillionZacks (Tue, Feb 26)
• 2 Misguided Points For (And Against) Amarinat Seeking Alpha (Tue, Feb 26)

Monday, February 25, 2013

• Qysmia, the Hurdles, and Your Appetite for Riskat Motley Fool (Mon, Feb 25)
• FDA Approves Roche's KadcylaZacks (Mon, Feb 25)
• Slideshow: An Evening with Master Chefs dinnerat bizjournals.com (Mon, Feb 25)
• What's Next for Dynavax?at Motley Fool (Mon, Feb 25)
• AbbVie: Don't Fear The Humira Patent Expirationat Seeking Alpha (Mon, Feb 25)

Sunday, February 24, 2013

• A Global Biotechnology Company in its 164th Yearat Motley Fool (Sun, Feb 24)
• Synergy Targets Root Cause Of Irritable Bowel Syndromeat Seeking Alpha (Sun, Feb 24)

Friday, February 22, 2013

• Roche Breast Cancer Drug To Succeed Herceptinat Investor's Business Daily (Fri, Feb 22)
• A Buyout In Amarin Is Imminent!at Motley Fool (Fri, Feb 22)
• Genentech wins FDA approval for 'smart bomb' against breast cancerat bizjournals.com (Fri, Feb 22)
• A Triumph In Breast Cancer -- And Another Expensive Drugat Forbes (Fri, Feb 22)
• EMA recommends extended indications for Glaxo's Cervarixtheflyonthewall.com (Fri, Feb 22)

Thursday, February 21, 2013

• Isis Pharmaceuticals Launches Trial, Hits Milestoneat Motley Fool (Thu, Feb 21)
• [$$] Novo's Pain Means Sanofi Shares Gainat Barrons.com (Thu, Feb 21)
• 5 Great Stocks Yielding 5%at Motley Fool (Thu, Feb 21)
• Glaxo/Theravance Seek US ApprovalZacks (Thu, Feb 21)
• GSK Makes Notable Cross Below Critical Moving Averageat Forbes (Thu, Feb 21)

Wednesday, February 20, 2013

• 5 Dividend Companies Favored by Top Investorsat Motley Fool (Wed, Feb 20)
• Puma Biotech fluctuates on cancer drug updateAP (Wed, Feb 20)
• GSK's HIV Drug Gets Priority ReviewZacks (Wed, Feb 20)
• A Pharmaceutical Growth Story You Can't Afford To Missat Motley Fool (Wed, Feb 20)

Add GSK News to My Yahoo!